Literature DB >> 7298626

Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites.

H L Gurtoo, A J Marinello, R F Struck, B Paul, R P Dahms.   

Abstract

Several lines of investigation were pursued to understand mechanisms involved in the in vivo depression of rat hepatic microsomal mixed function oxidase by cyclophosphamide, an important anti-cancer and immunosuppressive agent. Essentially exclusive metabolism-dependent binding to microsomal proteins of 14C from [4-14C]cyclophosphamide, compared with 3H from [chloroethyl-3H]cyclophosphamide, suggests the binding of the metabolite acrolein. Of the various metabolites and analogs of cyclophosphamide tested (which did not contain a peroxy or a hydroperoxy group), only acrolein and 4-hydroxycyclophosphamide (which releases acrolein in solution) caused denaturation of microsomal cytochrome P-450 in vitro; this denaturation was identical with that produced by sulfhydryl reagents. Of the various chemicals tested, only those which contained either a free amino group (except lysine) and/or a free sulfhydryl group (e.g. semicarbazide, cysteine, glycine, glucosamine) effectively blocked (40-80%) the binding of 14C as well as protected against acrolein-induced denaturation of cytochrome P-450. These data further suggested interaction of cyclophosphamide metabolite with free amino and/or free sulfhydryl groups in proteins. However, comparison with [3H]aflatoxin B2a which interacts with free protein amino groups via the formation of Schiff bases, clearly attributed the preferential binding of 14C to cysteine sulfhydryl groups in these proteins. Studies on chemical models derived from reaction between acrolein and cysteine also supported this suggestion. When microsomes isolated from incubations metabolizing [4-14C]cyclophosphamide were subjected to gel electrophoresis, the major radioactive band detected by autoradiography was associated with a cytochrome P-450 band at 55,000 daltons, the major band induced by phenobarbital in the rat. All these results taken together strongly point to the possibility that acrolein is the cyclophosphamide metabolite responsible for the depression of the mixed function oxidase activities. Acrolein most likely produces this effect by alkylation of the sulfhydryl group(s) in the active site of cytochrome P-450.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298626

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  The acrolein cytotoxicity and cytoprotective action of alpha-tocopherol in primary cultured rat hepatocytes.

Authors:  M Watanabe; M Sugimoto; K Ito
Journal:  Gastroenterol Jpn       Date:  1992-04

2.  Influence of protein binding on acrolein turnover in vitro by oxazaphosphorines and liver microsomes.

Authors:  Frank Baumann; Renate Schmidt; Jens Teichert; Rainer Preiss
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

3.  Chemical and biological mechanisms of phytochemical activation of Nrf2 and importance in disease prevention.

Authors:  Aimee L Eggler; Sergey N Savinov
Journal:  Recent Adv Phytochem       Date:  2013-12-03

4.  In vivo absorption, metabolism, and urinary excretion of alpha,beta-unsaturated aldehydes in experimental animals. Relevance to the development of cardiovascular diseases by the dietary ingestion of thermally stressed polyunsaturate-rich culinary oils.

Authors:  M Grootveld; M D Atherton; A N Sheerin; J Hawkes; D R Blake; T E Richens; C J Silwood; E Lynch; A W Claxson
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  In vivo protection by protein A of hepatic microsomal mixed function oxygenase system of cyclophosphamide-treated rats.

Authors:  M Dohadwala; P K Ray
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade—a single-center retrospective study.

Authors:  Juan Li; Guowei Dai; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2014-07-23       Impact factor: 2.980

7.  Cyclophosphamide-impaired regulation of hepatic heme metabolism.

Authors:  M Rizzardini; A Ferraroli; D Dal Fiume; L Cantoni
Journal:  Experientia       Date:  1984-12-15

Review 8.  P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.

Authors:  M Murray
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

9.  Effects of the induction of hepatic microsomal metabolism on the toxicity of cyclophosphamide.

Authors:  H L Gurtoo; S K Bansal; Z Pavelic; R F Struck
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.